Henry Schein (NASDAQ:HSIC) Posts Earnings Results, Beats Expectations By $0.04 EPS

Henry Schein (NASDAQ:HSIC) announced its earnings results on Tuesday. The company reported $0.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.86 by $0.04, RTT News reports. Henry Schein had a return on equity of 15.93% and a net margin of 4.66%. The company had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.52 billion. During the same period last year, the company posted $1.03 earnings per share. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year. Henry Schein updated its FY19 guidance to $3.41-3.47 EPS and its FY20 guidance to $3.65-3.75 EPS.

HSIC stock traded up $0.17 during midday trading on Friday, reaching $68.91. The stock had a trading volume of 905,245 shares, compared to its average volume of 1,554,308. The business has a fifty day simple moving average of $63.06 and a two-hundred day simple moving average of $65.31. The company has a quick ratio of 0.95, a current ratio of 1.63 and a debt-to-equity ratio of 0.30. The firm has a market cap of $10.04 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 2.62 and a beta of 0.85. Henry Schein has a twelve month low of $56.58 and a twelve month high of $72.81.

In related news, SVP Michael S. Ettinger sold 3,671 shares of Henry Schein stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $66.96, for a total value of $245,810.16. Following the completion of the sale, the senior vice president now directly owns 87,972 shares in the company, valued at $5,890,605.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Vice Chairman James P. Breslawski sold 6,856 shares of Henry Schein stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $66.96, for a total value of $459,077.76. Following the completion of the sale, the insider now owns 242,190 shares of the company’s stock, valued at $16,217,042.40. The disclosure for this sale can be found here. 1.06% of the stock is owned by company insiders.

A number of analysts have recently weighed in on HSIC shares. TheStreet upgraded Henry Schein from a “c+” rating to a “b” rating in a research note on Monday, October 14th. Barrington Research restated a “buy” rating and issued a $75.00 target price on shares of Henry Schein in a research note on Wednesday. William Blair lowered Henry Schein from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 7th. Cleveland Research restated a “hold” rating on shares of Henry Schein in a research note on Friday, November 1st. Finally, Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating and set a $71.00 target price for the company. in a research note on Wednesday. Six analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $73.50.

Henry Schein announced that its Board of Directors has approved a share buyback program on Thursday, October 31st that permits the company to repurchase $400.00 million in shares. This repurchase authorization permits the company to repurchase up to 4.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Read More: What does a dividend yield signify to investors?

Earnings History for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.